The 9/30/22 financials paint a grim picture. $19,000 in cash, $22,000,000 of current liabilities (including the HEPA debenture due within 1 year), ~ $1.3 mil of monthly operating expenses. 

The financials are stated in US dollars currently trading at 10 cents per share.

One quarter and 3.9 mil later and not a peep. They have got to be getting cash from somewhere to pay employees and operating expenses. If PPs are being floated to pay operating expenses we are looking at another 30-40 mil shares outstanding. Either there is a deal in the making or RVX is just another failed biotech.

How about some news? Lets get this over with one way or another.

Chicagoest